Fluvoxamine Treatment Guidelines

Clinical Response and Monitoring

The American Academy of Sleep Medicine suggests that statistically significant improvement with fluvoxamine may occur within 2 weeks, with clinically meaningful response typically by week 6, and maximal benefit by week 10-12 or later, in patients with sleep disorders 1, 2
The American Academy of Child and Adolescent Psychiatry recommends monitoring patients closely for suicidality, particularly those ≤24 years old, during the first months and after all dose adjustments, as well as watching for signs of serotonin syndrome and behavioral activation 3

The American Academy of Child and Adolescent Psychiatry advises that fluvoxamine is contraindicated with MAOIs due to the risk of serotonin syndrome, and that it has extensive CYP450 interactions, requiring caution when combining with other medications 3
The American Academy of Child and Adolescent Psychiatry also warns that fluvoxamine carries a higher risk of discontinuation syndrome, and that symptoms include dizziness, fatigue, myalgias, headaches, nausea, insomnia, sensory disturbances, anxiety, and agitation, emphasizing the importance of gradual tapering 3